Foundayo, Eli Lilly’s newly approved oral obesity medication, received 1,390 U.S. prescriptions during its first week of sales, according to IQVIA data for the week ended April 10 2026. The data were released on April 17 2026, the first commercial performance metric for the drug since its FDA approval on April 1 and its shipment to pharmacies on April 6.
Foundayo’s launch timeline mirrors that of its competitor, Novo Nordisk’s Wegovy. Wegovy generated 3,071 prescriptions in the first four days after its January 5 launch, indicating a stronger initial uptake. Foundayo’s 1,390 prescriptions in a full week represent a solid debut, though the figure is lower than Wegovy’s early numbers, reflecting the competitive intensity of the oral GLP‑1 market.
The drug’s pricing and distribution strategy are designed to maximize accessibility. Self‑pay pricing starts at $149 per month, while commercial insurance plans can cover it for as low as $25 per month through savings cards. Medicare coverage is expected by July 2026. Foundayo is available through LillyDirect, Amazon Pharmacy, and multiple telehealth platforms, and it can be taken without food or water restrictions, a convenience advantage over Wegovy’s dosing requirements.
From a revenue perspective, Foundayo’s early uptake is a key indicator for Lilly’s obesity portfolio forecasts. Analysts project that the drug will need approximately 5.4 million prescriptions from April through December 2026 to reach the $1.7 billion consensus estimate, and about 6 million prescriptions to hit $2 billion. In addition to weight‑loss indications, Phase 3 data show a 16% reduction in major heart events and a 57% reduction in risk of death versus insulin therapy in type 2 diabetes patients, positioning Foundayo for a potential diabetes indication that could broaden its market.
The launch of Foundayo, alongside Wegovy, expands the overall GLP‑1 market rather than merely shifting patients between products. Foundayo’s oral format, lower cost, and convenience are expected to capture a patient segment that prefers a daily pill over injections, complementing Lilly’s injectable obesity drug Zepbound, which offers higher efficacy but requires injection. The early prescription numbers, while modest compared to Wegovy, signal that Foundayo is gaining traction and will provide a steady stream of revenue as the drug scales.
In summary, Foundayo’s first‑week prescription count of 1,390 establishes a baseline for Lilly’s obesity revenue projections, highlights the drug’s competitive positioning, and underscores the company’s strategy to broaden access through pricing and distribution. The data provide a clear early indicator of market penetration and inform Lilly’s outlook for the remainder of 2026.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.